US 9,808,489 B2
Treatment of heart disease
Piero Anversa, New York, NY (US); and Annarosa Leri, Boston, MA (US)
Assigned to AAL Scientifics, Inc., New York, NY (US)
Filed by AAL Scientifics, Inc., New York, NY (US)
Filed on Apr. 22, 2016, as Appl. No. 15/135,774.
Application 15/135,774 is a division of application No. 13/508,838, abandoned, previously published as PCT/US2010/055993, filed on Nov. 9, 2010.
Claims priority of provisional application 61/259,351, filed on Nov. 9, 2009.
Prior Publication US 2016/0220614 A1, Aug. 4, 2016
Int. Cl. C12N 5/0775 (2010.01); A61K 35/54 (2015.01); A61K 35/34 (2015.01); C12N 5/077 (2010.01); A61K 35/12 (2015.01)
CPC A61K 35/34 (2013.01) [C12N 5/0657 (2013.01); C12N 5/0662 (2013.01); A61K 35/12 (2013.01); C12N 2501/105 (2013.01)] 16 Claims
 
1. A method of treating cardiac stem cells to be administered to a subject in need thereof, comprising:
a. contacting a population of cardiac stem cells with an effective amount of IGF-2or a variant thereof;
b. administering the population of cardiac stem cells from step (a) to the subject in need thereof;
wherein the effective amount of IGF-2 or a variant thereof is sufficient to increase expression of at least one marker for myocyte differentiation by at least about 10%, as compared to cardiac stem cells in the absence of IGF-2 or a variant thereof.